Claims for Patent: 8,163,798

Summary for Patent: 8,163,798

Title:	Methods and devices for providing prolonged drug therapy
Abstract:	Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s):	Gupta; Suneel K. (Sunnyvale, CA), Guinta; Diane R. (Palo Alto, CA), Christopher; Carol A. (Belmont, CA), Saks; Samuel R. (Burlingame, CA), Hamel; Lawrence G. (Mountain View, CA)
Assignee:	Alza Corporation (Palo Alto, CA)
Application Number:	10/639,355
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,163,798
Patent Claims:	1. An oral tablet dosage form for the treatment of Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject comprising: an immediate release portion comprising methylphenidate or a pharmaceutically effective salt thereof; and a sustained release portion comprising methylphenidate or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier, wherein: said dosage form releases said methylphenidate over a period comprising first, second, and third sequential one-hour time intervals, and said sustained release portion releases more of said methylphenidate during said second interval than during said first interval, and more of said methylphenidate during said third interval than during said second interval. 2. The dosage form according to claim 1 wherein the methylphenidate released during said first interval only includes methylphenidate released from said immediate release portion. 3. The dosage form according to claim 1 wherein said period of release comprises a fourth sequential time interval, and wherein the sustained release portion releases more of said methylphenidate during said fourth interval than during said third interval. 4. The dosage form according to claim 1 wherein said immediate release portion is applied as a coating on an outer surface of the dosage form. 5. The dosage form according to claim 1 wherein said immediate release portion and said sustained release portion comprise methylphenidate hydrochloride. 6. The dosage form according to claim 5 wherein said methylphenidate hydrochloride in said immediate release portion constitutes about 25% of said methylphenidate hydrochloride in said dosage form. 7. An oral tablet dosage form for the treatment of Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject comprising: an immediate release coating comprising methylphenidate hydrochloride; and a sustained release portion comprising methylphenidate hydrochloride and a pharmaceutically acceptable carrier, wherein: said dosage form provides release of said methylphenidate hydrochloride over a period comprising first, second, third, and fourth sequential one-hour time intervals; said sustained release portion releases more of said methylphenidate hydrochloride during said second interval than during said first interval, more of said methylphenidate hydrochloride during said third interval than during said second interval, and more of said methylphenidate hydrochloride during said fourth interval than during said third interval; the methylphenidate hydrochloride released during said first interval only includes methylphenidate hydrochloride released from said immediate release coating. 8. The dosage form according to claim 1 wherein said dosage form is osmotic. 9. The dosage form according to claim 1 wherein said dosage form is non-osmotic. 10. The dosage form according to claim 7 wherein said dosage form is osmotic. 11. The dosage form according to claim 7 wherein said dosage form is non-osmotic.